Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Katarina Sjögreen Gleisner

Professor

Default user image.

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Författare

  • Anna Sundlöv
  • Katarina Sjögreen-Gleisner
  • Johanna Svensson
  • Michael Ljungberg
  • Tomas G Olsson
  • Peter Bernhardt
  • Jan Tennvall

Summary, in English

Purpose: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). Method: Treatment was given with repeated cycles of 7.4 GBq 177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging). All patients received treatment up to a renal BED of 27 ± 2 Gy (α/β = 2.6 Gy) (Step 1). Selected patients were offered further treatment up to a renal BED of 40 ± 2 Gy (Step 2). Renal function was followed by estimation and measurement of the glomerular filtration rate (GFR). Results: Fifty-one patients were included in the present analysis. Among the patients who received treatment as planned, the median number of cycles in Step 1 was 5 (range 3-7), and for those who completed Step 2 it was 7 (range 5-8); 73% were able to receive >4 cycles. Although GFR decreased in most patients after the completion of treatment, no grade 3-4 toxicity was observed. Patients with a reduced baseline GFR seemed to have an increased risk of GFR decline. Five patients received treatment in Step 2, none of whom exhibited a significant reduction in renal function. Conclusions: Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.

Avdelning/ar

  • Tumörmikromiljö
  • Medicinsk strålningsfysik, Lund
  • Nuclear Medicine Physics
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publiceringsår

2017-03-22

Språk

Engelska

Sidor

1480-1489

Publikation/Tidskrift/Serie

European Journal of Nuclear Medicine and Molecular Imaging

Volym

44

Issue

9

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Cancer and Oncology
  • Radiology, Nuclear Medicine and Medical Imaging
  • Other Physics Topics

Nyckelord

  • Lu-DOTATATE
  • Dosimetry
  • Neuroendocrine
  • PRRT
  • Renal function

Aktiv

Published

Forskningsgrupp

  • Nuclear Medicine Physics

ISBN/ISSN/Övrigt

  • ISSN: 1619-7070